{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Blumberg EA"],"funding":["Center for Cellular Immunotherapies - internal funding from the University of Pennsylvania","Center for Cellular Immunotherapies, University of Pennsylvania"],"pagination":["e155682"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9220832"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(11)"],"pubmed_abstract":["BACKGROUNDCOVID-19 remains a global health emergency with limited treatment options, lagging vaccine rates, and inadequate healthcare resources in the face of an ongoing calamity. The disease is characterized by immune dysregulation and cytokine storm. Cyclosporine A (CSA) is a calcineurin inhibitor that modulates cytokine production and may have direct antiviral properties against coronaviruses.METHODSTo test whether a short course of CSA was safe in patients with COVID-19, we treated 10 hospitalized, oxygen-requiring, noncritically ill patients with CSA (starting at a dose of 9 mg/kg/d). We evaluated patients for clinical response and adverse events, measured serum cytokines and chemokines associated with COVID-19 hyperinflammation, and conducted gene-expression analyses.RESULTSFive part"],"journal":["JCI insight"],"pubmed_title":["A phase I trial of cyclosporine for hospitalized patients with COVID-19."],"pmcid":["PMC9220832"],"funding_grant_id":["n/a","no funding number (internal funding)"],"pubmed_authors":["Bailey CM","Tebas P","Carulli A","Chew A","Blumberg EA","Veloso EA","Schmidt AH","Chavda K","Noorchashm H","Barnette T","Church SE","Noll JH","Rogal W","Hwang WT","Hexner EO","Martins R","Gaymon AL","Hudson BM","June CH","Jurek R","Marshall A","Fraietta JA","Frank I"],"additional_accession":[]},"is_claimable":false,"name":"A phase I trial of cyclosporine for hospitalized patients with COVID-19.","description":"BACKGROUNDCOVID-19 remains a global health emergency with limited treatment options, lagging vaccine rates, and inadequate healthcare resources in the face of an ongoing calamity. The disease is characterized by immune dysregulation and cytokine storm. Cyclosporine A (CSA) is a calcineurin inhibitor that modulates cytokine production and may have direct antiviral properties against coronaviruses.METHODSTo test whether a short course of CSA was safe in patients with COVID-19, we treated 10 hospitalized, oxygen-requiring, noncritically ill patients with CSA (starting at a dose of 9 mg/kg/d). We evaluated patients for clinical response and adverse events, measured serum cytokines and chemokines associated with COVID-19 hyperinflammation, and conducted gene-expression analyses.RESULTSFive part","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2026-07-14T21:51:29.885Z","creation":"2024-11-09T21:14:06.399Z"},"accession":"S-EPMC9220832","cross_references":{"pubmed":["35536669"],"doi":["10.1172/jci.insight.155682"]}}